Mycophenolate: all 50 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant RecipientsNot yet recruitingNCT05872568Phase 4
• Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)CompletedNCT01044303Phase 4Results posted
• Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell TransplantCompletedNCT00810602Phase 1/2Results posted
• Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell TransplantCompletedNCT00639717Phase 2Results posted
• Myfortic or CellCept Gastrointestinal Effects in African American Kidney RecipientsTerminatedNCT00522548Phase 4Results posted
• Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant RecipientsTerminatedNCT00434590Phase 4Results posted
• Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.CompletedNCT00425308Phase 3Results posted
• Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant PatientsCompletedNCT00419926Phase 4Results posted
• Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant RecipientsCompletedNCT00405652Phase 3Results posted
• Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) IntoleranceCompletedNCT00400400Phase 4Results posted
• Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant PatientsCompletedNCT00369278Phase 3Results posted
• Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With MycophenolateCompletedNCT00351377Phase 3Results posted
• Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant RecipientsCompletedNCT00284934Phase 3Results posted
• Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney TransplantsCompletedNCT00267150Phase 3Results posted
• Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney TransplantationCompletedNCT00239005Phase 4Results posted
• Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor SourceCompletedNCT02167958Phase 1
• Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus ManifestationsCompletedNCT01112215Phase 4
• Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus TherapyStatus unknownNCT00966836Phase 3
• Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart PatientsCompletedNCT00574743Phase 4
• Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant RecipientsCompletedNCT00537862Phase 4
• Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) SymptomsCompletedNCT00529269Phase 4
• Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate MofetilCompletedNCT00400647Phase 4
• Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant RecipientsCompletedNCT00312143Phase 4
• Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOSCompletedNCT00308425Phase 3
• MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C PositiveTerminatedNCT00284921Phase 3
• Mycophenolate for Pulmonary SarcoidosisTerminatedNCT00262132Phase 3
• Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant RecipientsCompletedNCT00241059Phase 4
• Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney RecipientsCompletedNCT00240955Phase 4
• Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant PatientsCompletedNCT00239083Phase 4
• Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant RecipientsCompletedNCT00239070Phase 3
• Study of Enteric-coated Mycophenolate Sodium Maintenance Therapy in Patients With Renal Transplant Receiving Cyclosporine Microemulsion and Steroids,CompletedNCT00239057Phase 3
• An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant RecipientsCompletedNCT00239044Phase 3
• Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term SteroidsCompletedNCT00239031Phase 3
• Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant PatientsCompletedNCT00239018Phase 4
• Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.CompletedNCT00238992Phase 3
• A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)CompletedNCT00238979Phase 4
• Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate MofetilCompletedNCT00238966Phase 4
• Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant RecipientsCompletedNCT00238953Phase 4
• Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney TransplantsCompletedNCT00238940Phase 3
• Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving TacrolimusCompletedNCT00171392Phase 3
• Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal TransplantCompletedNCT00171379Phase 3
• A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.CompletedNCT00154245Phase 4
• Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)CompletedNCT00154232Phase 4
• Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant PatientsCompletedNCT00154206Phase 4
• Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI IntoleranceCompletedNCT00150020Phase 4
• Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)CompletedNCT00150007Phase 4
• Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)CompletedNCT00149968Phase 4
• Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) TherapyCompletedNCT00149942Phase 4

← Mycophenolate overview